Utah People's Post

The Latest News from the Beehive State

Monday, April 19, 2021
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / Cholesterol Reducing Drug Alirocumab Successfully Passed ODYSSEY Trials

Cholesterol Reducing Drug Alirocumab Successfully Passed ODYSSEY Trials

January 9, 2015 Posted by Contributor

cholesterol reducing drug alirocumab successfully passed ODYSSEY trialsThe two pharmaceutical companies Regeneron Pharmaceuticals and Sanofi reported that the cholesterol reducing drug alirocumab has successfully passed the two new ODYSSEY trials. This is the first out of a 3 stage evaluation.

The two trials evaluated the efficacy of a treatment based on alirocumab that was administered every four weeks. The tests compared the reduction from baseline in low-density lipoprotein cholesterol or LDL-C (also known as “bad cholesterol”) in 2 groups of patients with high levels of blood cholesterol (or hypercholesterolemia). One was treated with alirocumab over a period of 24 weeks, and the other was given placebo.

This new drug belongs to the monoclonal antibody category, targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

In regards to the new trial, Bill Sasiela, Ph.D., Vice President, Program Direction, Cardiovascular and Metabolic at Regeneron explained:

“In the new monthly dosing trials, ODYSSEY CHOICE I and CHOICE II, the mean percent reduction in LDL-C from baseline was consistent with that seen in previous phase 3 trials evaluating alirocumab every other week dosing,”

This study is part of a bigger research that aims to establish the correct doses and intervals at which patients needing lipid-lowering treatment would take alirocumab.

The first trial, ODYSSEY CHOICE I, aimed to determine the drug’s efficacy and safety.  803 patients diagnosed with hypercholesterolemia at moderate to high cardiovascular (CV) risk took part in the study. They were divided into two groups. One group was treated with alirocumab in doses of  300 mg every four weeks and the other received placebos. More than two-thirds (68 percent) of patients were given statin medication.

ODYSSEY CHOICE II had the same goals but on a different patient category. The participants were 233 patients with hypercholesterolemia with high CV risk and/or a history of intolerance to two or more statins. Two groups were established. Doses of 150 mg alirocumab were administered every four weeks to the patients in the test group. The second group took placebos. There was no statin therapy involved in this second trial.

Although a promising compound, alirocumab does have some side effects. At least 5 percent of the patients treated with this medication developed injection site reactions, headache, infections of the upper respiratory tract, neuralgic joint pain, nausea, sinusitis, pain in extremity and fatigue.

In both trials, patients treated with the compound whose LDL-C levels were reduced by less than 30 percent at the end of the treatment, received 150 mg doses of alirocumab every two weeks at 12 weeks.

The drug is still under clinical development.
Image Source: Women World

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health Tagged With: alirocumab does have side effects, cholesterol reducing drug alirocumab successfully passed ODYSSEY trials, injection site reactions; headache; infections of the upper respiratory tract; neuralgic joint pain; nausea; sinusitis; pain in extremity and fatigue, Regeneron Pharmaceuticals and Sanofi reported alirocumab successfully passed two new ODYSSEY trials

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

June 29, 2018 By Amelia Donovan

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

June 29, 2018 By Amelia Donovan

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

June 28, 2018 By Amelia Donovan

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

June 27, 2018 By Amelia Donovan

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

June 27, 2018 By Amelia Donovan

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

June 26, 2018 By Amelia Donovan

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

June 25, 2018 By Amelia Donovan

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

June 23, 2018 By Amelia Donovan

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

June 22, 2018 By Amelia Donovan

456 People Dead at U.K. Hospital after Taking too Many Painkillers

June 21, 2018 By Amelia Donovan

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

June 20, 2018 By Amelia Donovan

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

    Jun 29, 2018
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

    Jun 29, 2018
  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

    Jun 27, 2018
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

    Jun 25, 2018
  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

    Jun 22, 2018
  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

    Jun 21, 2018
  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

    Jun 19, 2018
  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

    Jun 18, 2018
  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

    Jun 15, 2018
  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

    Jun 13, 2018

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2021 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.